12:00 AM
Dec 17, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Qnasl beclomethasone dipropionate nasal aerosol: Additional Phase III data

Additional data from a double-blind, U.S. Phase III trial in 529 patients ages 12 and older showed that there were no clinically important differences in intraocular pressure (IOP) between the once-daily 320 µg Qnasl and placebo arms during the 52-week treatment period. IOP remained within the normal range of <21 mmHg...

Read the full 234 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >